Australian Clinical Labs Limited Stock

Equities

ACL

AU0000148496

Healthcare Facilities & Services

Market Closed - Australian S.E. 02:10:46 2024-04-30 am EDT 5-day change 1st Jan Change
2.43 AUD -0.82% Intraday chart for Australian Clinical Labs Limited -0.41% -15.92%
Sales 2024 * 683M 446M Sales 2025 * 711M 464M Capitalization 491M 321M
Net income 2024 * 29M 18.93M Net income 2025 * 38M 24.8M EV / Sales 2024 * 0.78 x
Net Debt 2024 * 39.25M 25.62M Net Debt 2025 * 17.81M 11.63M EV / Sales 2025 * 0.72 x
P/E ratio 2024 *
17.2 x
P/E ratio 2025 *
12.7 x
Employees 5,115
Yield 2024 *
3.51%
Yield 2025 *
4.63%
Free-Float 55.78%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Australian Clinical Labs Limited

1 day-0.82%
1 week-0.41%
Current month-9.67%
1 month-9.67%
3 months-20.07%
6 months-8.30%
Current year-15.92%
More quotes
1 week
2.43
Extreme 2.43
2.55
1 month
2.36
Extreme 2.36
2.71
Current year
2.26
Extreme 2.26
3.15
1 year
2.26
Extreme 2.26
3.69
3 years
2.26
Extreme 2.26
6.39
5 years
2.26
Extreme 2.26
6.39
10 years
2.26
Extreme 2.26
6.39
More quotes
Managers TitleAgeSince
Chief Executive Officer - 14-12-31
Director of Finance/CFO - 14-12-31
Chief Tech/Sci/R&D Officer - 08-12-31
Members of the board TitleAgeSince
Chairman 56 14-12-31
Director/Board Member 67 21-04-27
Director/Board Member - 23-08-22
More insiders
Date Price Change Volume
24-04-30 2.43 -0.82% 94 036
24-04-29 2.45 -0.41% 144,588
24-04-26 2.46 -1.20% 246,118
24-04-24 2.49 +2.05% 198,250
24-04-23 2.44 +1.24% 258,572

Delayed Quote Australian S.E., April 30, 2024 at 02:10 am EDT

More quotes
Australian Clinical Labs Limited is a private provider of pathology services. Its laboratories perform a range of pathology tests each year for a range of clients, including doctors, specialists, patients, hospitals, and corporate clients. It performs a range of services for doctors, patients, and corporate clients, including routine pathology tests, advanced molecular genetics testing, harmony NIPT and first trimester screening, genetic carrier screening, chemical pathology, histopathology and cytopathology, hematology, allergy and immunology, serology and microbiology, infectious molecular testing, cardiac testing services, functional pathology, veterinary pathology, and commercial drug and alcohol testing. Its specialist services include molecular cancer services, obstetrics and gynecology, pharmacogenetic testing, gastroenterology, and hospital services. It has operations in Victoria, New South Wales, Western Australia, South Australia, Queensland, and the Northern Territory.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
2.45 AUD
Average target price
3.096 AUD
Spread / Average Target
+26.36%
Consensus